Alpha Profiles · Company Profile

IRONWOOD PHARMACEUTICALS INC

Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions.

https://registry.alpha.ac/companies/ironwood-pharmaceuticals-inc

Entity: Public listing published
Primary listing: NASDAQ: IRWD
Verification: Partially verified
Last reviewed: 2026-09-14T14:36:31.481633+00:00

Overview

Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

5 public records

Gregory Martinez

Senior Vice President, Chief Financial Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001104659-26-050325Apr 28, 2026

John Minardo

Senior Vice President, Chief Legal Officer and Secretary

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001104659-26-050325Apr 28, 2026

Michael Shetzline, M.D., Ph.D.

Senior Vice President, Chief Medical Officer and Head of Research and Drug Development

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001104659-26-050325Apr 28, 2026

Tammy Gaskins

Senior Vice President, Chief Commercial Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001104659-26-050325Apr 28, 2026

Thomas McCourt

Chief Executive Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001104659-26-050325Apr 28, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 14, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.